drugset
drugset / Trial / NCT01415674

Research of Biomarkers of Activity and Efficacy of BIBW2992 in Untreated Non-metastatic HNSCC Patients

NCT01415674 ↗

Phase 2 Completed 61 enrolled UNICANCER
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to identify predictive and pharmacodynamic biomarkers of activity and efficacy of pre-operative Afatinib (BIBW2992) in untreated non-metastatic head and neck squamous cell carcinoma patients

Timeline

Start
2012-01
Primary completion
2021-12
Completion
2021-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Afatinib Small molecule 40 mg Oral

Indications

head and neck squamous cell carcinoma